Graft vs Host Disease Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharma, Regimmune Corporation

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Graft vs Host Disease pipeline constitutes 45+ key companies continuously working towards developing 50+ Graft vs Host Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Graft vs Host Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graft vs Host Disease Market.

The Graft vs Host Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Graft vs Host Disease Pipeline Report: https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Graft vs Host Disease treatment therapies with a considerable amount of success over the years.
• Graft vs Host Disease companies working in the treatment market are Abbisko Therapeutics, Theriva Biologics, Seres Therapeutics, Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others, are developing therapies for the Graft vs Host Disease treatment
• Emerging Graft vs Host Disease therapies in the different phases of clinical trials are- ABSK021, SYN-004, SER-155, CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others are expected to have a significant impact on the Graft vs Host Disease market in the coming years.
• In September 2024, ReAlta Life Sciences, a US-based biopharmaceutical company, has administered the first dose in its Phase II clinical trial of RLS-0071 for the treatment of steroid-refractory acute graft-versus-host disease (aGvHD). This open-label, dose-escalation study aims to evaluate the tolerability, safety, pharmacokinetics, pharmacodynamics, dosing, and efficacy of RLS-0071 as a secondary treatment for aGvHD in patients unresponsive to steroid therapy. Participants will receive RLS-0071 for seven or 14 days, either alone or in combination with the standard treatment, ruxolitinib.
• In July 2024, Tr1X has administered the first dose to a patient in the TRX103-01 clinical trial, which is evaluating TRX103, a Type 1 Treg (Tr1) cell therapy for preventing Graft-versus-Host Disease (GvHD). The trial aims to assess the safety, pharmacokinetics, and pharmacodynamics of TRX103 in patients with hematologic malignancies undergoing mismatched hematopoietic stem cell transplantation (HSCT), focusing on GvHD prevention.

Graft vs Host Disease Overview
Graft-versus-host disease (GVHD) is a condition that occurs after a stem cell or bone marrow transplant, where the transplanted immune cells (graft) attack the recipient's body (host). This happens when the donor's immune cells recognize the recipient's tissues as foreign. GVHD can affect various organs, including the skin, liver, and gastrointestinal tract, and can cause symptoms such as rashes, jaundice, diarrhea, and abdominal pain. GVHD is a major complication of bone marrow transplants and can range from mild to severe. It is treated with medications to suppress the immune system.

Get a Free Sample PDF Report to know more about Graft vs Host Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Graft vs Host Disease Drugs Under Different Phases of Clinical Development Include:
• ABSK021: Abbisko Therapeutics
• SYN-004: Theriva Biologics
• SER-155: Seres Therapeutics
• CB103: Cellestia Biotech
• Glasdegib: Pfizer
• TQ 05105: Chia Tai Tianqing Pharmaceutical
• RGI-2001: Regimmune Corporation
• Axatilimab: Syndax Pharmaceuticals
• MaaT013: MaaT Pharma
• MC 0518: Medac
• Itolizumab: Equillium
• Elranatamab: Pfizer
• Felzartamab: Janssen Pharmaceutical
• T-Guard: Xenikos
• MaaT013: MaaT Pharma
• Axatilimab: Syndax Pharmaceuticals
• TQ 05105: Chia Tai Tianqing Pharmaceutical Group

Graft vs Host Disease Route of Administration
Graft vs Host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous

Graft vs Host Disease Molecule Type
Graft vs Host Disease Products have been categorized under various Molecule types, such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Graft vs Host Disease Pipeline Therapeutics Assessment
• Graft vs Host Disease Assessment by Product Type
• Graft vs Host Disease By Stage and Product Type
• Graft vs Host Disease Assessment by Route of Administration
• Graft vs Host Disease By Stage and Route of Administration
• Graft vs Host Disease Assessment by Molecule Type
• Graft vs Host Disease by Stage and Molecule Type

DelveInsight's Graft vs Host Disease Report covers around 65+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Graft vs Host Disease product details are provided in the report. Download the Graft vs Host Disease pipeline report to learn more about the emerging Graft vs Host Disease therapies
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Graft vs Host Disease Therapeutics Market include:
Key companies developing therapies for Graft vs Host Disease are - Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Medsenic, Xenothera, Xenikos, AltruBio Inc., Biogen, OncoImmune, Inc., Cellect Biotechnology, AstraZeneca, Bristol-Myers Squibb, Dystrogen Therapeutics, CTI BioPharma, Ossium Health, Inc., Orca Biosystems, Inc., Synthetic Biologics Inc., Cellenkos, Corvus Pharmaceuticals, ImStem Biotechnology, Rheos Medicines, Equillium, Cellestia Biotech, Genentech, Humanigen, CSL Behring, ADIENNE, and others.

Graft vs Host Disease Pipeline Analysis:
The Graft vs Host Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Graft vs Host Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graft vs Host Disease Treatment.
• Graft vs Host Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Graft vs Host Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graft vs Host Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Graft vs Host Disease drugs and therapies
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Graft vs Host Disease Pipeline Market Drivers
• Increase in the number of patients suffering from chronic GvHD, robust Pipeline of GvHD are some of the important factors that are fueling the Graft vs Host Disease Market.

Graft vs Host Disease Pipeline Market Barriers
• However, high cost of treatment, recognizing the limitations of currently available aGVHD therapies and other factors are creating obstacles in the Graft vs Host Disease Market growth.

Scope of Graft vs Host Disease Pipeline Drug Insight
• Coverage: Global
• Key Graft vs Host Disease Companies: Abbisko Therapeutics, Theriva Biologics, Seres Therapeutics, Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others
• Key Graft vs Host Disease Therapies: ABSK021, SYN-004, SER-155, CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others
• Graft vs Host Disease Therapeutic Assessment: Graft vs Host Disease current marketed and Graft vs Host Disease emerging therapies
• Graft vs Host Disease Market Dynamics: Graft vs Host Disease market drivers and Graft vs Host Disease market barriers

Request for Sample PDF Report for Graft vs Host Disease Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Graft vs Host Disease Report Introduction
2. Graft vs Host Disease Executive Summary
3. Graft vs Host Disease Overview
4. Graft vs Host Disease- Analytical Perspective In-depth Commercial Assessment
5. Graft vs Host Disease Pipeline Therapeutics
6. Graft vs Host Disease Late Stage Products (Phase II/III)
7. Graft vs Host Disease Mid Stage Products (Phase II)
8. Graft vs Host Disease Early Stage Products (Phase I)
9. Graft vs Host Disease Preclinical Stage Products
10. Graft vs Host Disease Therapeutics Assessment
11. Graft vs Host Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Graft vs Host Disease Key Companies
14. Graft vs Host Disease Key Products
15. Graft vs Host Disease Unmet Needs
16 . Graft vs Host Disease Market Drivers and Barriers
17. Graft vs Host Disease Future Perspectives and Conclusion
18. Graft vs Host Disease Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Graft vs Host Disease Market https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Graft vs Host Disease-Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Graft vs Host Disease Epidemiology https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Graft vs Host Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.